Insuman Rapid

Insulin Human, the active ingredient in Insuman Rapid, is an insulin presented as an injectable solution for subcutaneous or intravenous use. It is used to control blood glucose in patients with type 1 diabetes mellitus and in type 2 diabetes mellitus when insulin therapy is required. It provides a rapid onset of action, facilitating post‑prandial glucose control.

GNH USA supplies Insuman Rapid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Insuman Rapid, a rapid‑acting human insulin, is indicated for glycemic control in diabetes mellitus.

- Type 1 diabetes mellitus: provides rapid post‑prandial glucose reduction. - Type 2 diabetes mellitus requiring insulin therapy: assists in achieving target blood‑glucose levels. - Hospitalised patients with acute hyperglycaemia: enables quick correction of elevated glucose.

Adverse reactions may occur with any insulin therapy.

Common Side Effects: - Hypoglycaemia: symptoms of low blood sugar such as sweating, tremor, or confusion. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with improved glycaemic control. - Lipodystrophy: localized changes in fat tissue at repeated injection sites.

Serious or Rare Side Effects: - Severe hypoglycaemia requiring assistance. - Anaphylactic reaction: rare but potentially life‑threatening allergic response. - Edema: fluid retention leading to swelling, particularly in the lower extremities. - Persistent hyperglycaemia: inadequate response necessitating medical review.

Insuman Rapid requires careful clinical monitoring and patient education.

- Dose adjustment: titrate based on frequent blood‑glucose measurements. - Hypoglycaemia risk: avoid administration when blood glucose is already low. - Pregnancy and lactation: use only if clearly needed and under medical supervision. - Renal or hepatic impairment: monitor closely and adjust dose as required. - Concomitant medications: assess for agents that may mask hypoglycaemia symptoms. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Rapid may interact with other drugs affecting glucose metabolism.

Major Interactions (Avoid): - Other insulin or insulin secretagogues (e.g., sulfonylureas): risk of severe hypoglycaemia. - Alcohol: can potentiate hypoglycaemia, especially with fasting.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask typical hypoglycaemia warning signs. - Corticosteroids: can increase blood‑glucose levels, requiring dose adjustments. - Thiazide diuretics: may raise glucose concentrations, necessitating closer monitoring.